Prospects for angiotensin receptor blockers in diabetic retinopathy

Diabetes Research and Clinical Practice

Volumn 76, Issue 3 SUPPL., 2007, Pages

  Sjølie, Anne Katrin ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Candesartan; Diabetes; Renin angiotensin system; Retinopathy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; CANDESARTAN; CORTICOSTEROID; LISINOPRIL; PROTEIN KINASE C INHIBITOR; SOMATOSTATIN DERIVATIVE; STATINE DERIVATIVE;

BLINDNESS; BLOOD PRESSURE REGULATION; CLINICAL PRACTICE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE COURSE; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PROLIFERATIVE RETINOPATHY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLINDNESS; BLOOD PRESSURE; CLINICAL TRIALS; DIABETIC ANGIOPATHIES; DIABETIC DIET; DIABETIC RETINOPATHY; HUMANS; HYPERTENSION;

EID: 33947625093     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2007.01.015     Document Type: Review

References (43)

1. Sjolie A.K. Ocular complications in insulin treated diabetes mellitus. An epidemiological study. Acta Ophthalmol. Suppl. 172 (1985) 1-77
2. Sjolie A.K., Stephenson J., Aldington S., Kohner E., Janka H., Stevens L., et al. Retinopathy and vision loss in insulin-dependent diabetes in Europe. The EURODIAB IDDM complications study. Ophthalmology 104 2 (1997) 252-260
3. Agardh E., Agardh C.D., and Hansson-Lundblad C. The five-year incidence of blindness after introducing a screening programme for early detection of treatable diabetic retinopathy. Diabet. Med. 10 (1993) 555-559
4. Cormack T.G., Grant B., Macdonald M.J., Steel J., and Campbell I.W. Incidence of blindness due to diabetic eye disease in Fife 1990-91. Br. J. Ophthalmol. 85 (2001) 354-356
5. Icks A., Trautner C., Haastert B., Berger M., and Giani G. Blindness due to diabetes: population-based age- and sex-specific incidence rates. Diabet. Med. 14 (1997) 571-575
6. Clermont A., Bursell S.-E., and Feener E.P. Role of the angiotensin II type 1 receptor in the pathogenesis of diabetic retinopathy: effects of blood pressure control and beyond. J. Hypertens. 24 Suppl. 1 (2006) S73-S80
7. Klein R. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch. Ophthalmol. 102 (1984) 520-526
8. Klein R., Klein B.E., Moss S.E., Davis M.D., and DeMets D.L. The Wisconsin epidemiologic study of diabetic retinopathy when age at diagnosis is 30 or more years. Arch. Ophthalmol. 102 (1984) 527-532
9. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group, Lancet 352 (1998) 854-865.
10. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group, BMJ 317 (1998) 703-713.
11. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group, N. Engl. J. Med. 329 (1993) 977-986.
12. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial, Arch. Ophthalmol. 113 (1995) 36-51.
13. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group, N. Engl. J. Med. 342 (2000) 381-389.
14. Klein R., Klein B.E., Moss S.E., and Cruickshanks K.J. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 105 (1998) 1801-1815
15. Klein R., Klein B.E., Moss S.E., Davis M.D., and DeMets D.L. Is blood pressure a predictor of the incidence or progression of diabetic retinopathy?. Arch. Intern. Med. 149 (1989) 2427-2432
16. Schrier R.W., Estacio R.O., Esler A., and Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 61 (2002) 1086-1097
17. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings, Ophthalmology 85 (1978) 82-106.
18. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group, Ophthalmology 98 (5 Suppl.) (1991) 766-785.
19. Elliott A., and Flanagan D. Macular detachment following laser treatment for proliferative diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 228 (1990) 438-441
20. Schatz H., Madeira D., McDonald H.R., and Johnson R.N. Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. Arch. Ophthalmol. 109 (1991) 1549-1551
21. Akduman L., and Olk R.J. Subthreshold (invisible) modified grid diode laser photocoagulation in diffuse diabetic macular edema (DDME). Ophthalmic Surg. Lasers 30 (1999) 706-714
22. Moorman C.M., and Hamilton A.M. Clinical applications of the MicroPulse diode laser. Eye 13 (1999) 145-150
23. Laursen M.L., Møller F., Sander B., and Sjølie A.K. Subthreshold micropulse diode laser treatment in diabetic macular oedema. Br. J. Ophthalmol. 88 (2004) 1173-1179
24. Sjølie A.K., and Møller F. Medical management of diabetic retinopathy. Diabet. Med. 21 (2004) 666-672
25. Danser A.H., van den Dorpel M.A., Deinum J., Derkx F.H., Franken A.A., Peperkamp E., et al. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J. Clin. Endocrinol. Metab. 68 (1989) 160-167
26. Otani A., Takagi H., Suzuma K., and Honda Y. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ. Res. 82 (1998) 619-628
27. Wagner J., Jan Danser A.H., Derkx F.H., de Jong T.V., Paul M., Mullins J.J., et al. Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. Br. J. Ophthalmol. 80 (1996) 159-163
28. Fernandez L.A., Twickler J., and Mead A. Neovascularization produced by angiotensin II. J. Lab. Clin. Med. 105 (1985) 141-145
29. Aiello L.P., Bursell S.E., Clermont A., Duh E., Ishii H., Takagi C., et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 46 (1997) 1473-1480
30. Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Jampel H.D., Shah S.T., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331 (1994) 1480-1487
31. Hogeboom van Buggenum I.M., Polak B.C., Reichert-Thoen J.W., Vries-Knoppert W.A., van Hinsbergh V.W., and Tangelder G.J. Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy. Diabetologia 45 (2002) 203-209
32. Funatsu H., Yamashita H., Nakanishi Y., and Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br. J. Ophthalmol. 86 (2002) 311-315
33. Moravski C.J., Kelly D.J., Cooper M.E., Gilbert R.E., Bertram J.F., Shahinfar S., et al. Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension 36 (2000) 1099-1104
34. Nagisa Y., Shintani A., and Nakagawa S. The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats. Diabetologia 44 (2001) 883-888
35. Larsen M., Hommel E., Parving H.H., and Lund-Andersen H. Protective effect of captopril on the blood-retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 228 (1990) 505-509
36. Chase H.P., Garg S.K., Harris S., Hoops S., Jackson W.E., and Holmes D.L. Angiotensin-converting enzyme inhibitor treatment for young normotensive diabetic subjects: a two-year trial. Ann. Ophthalmol. 25 (1993) 284-289
37. Ravid M., Savin H., Lang R., Jutrin I., Shoshana L., and Lishner M. Proteinuria, renal impairment, metabolic control, and blood pressure in type 2 diabetes mellitus. A 14-year follow-up report on 195 patients. Arch. Intern. Med. 152 (1992) 1225-1229
38. Chaturvedi N., Sjølie A.K., Stephenson J.M., Abrahamian H., Keipes M., Castellarin A., et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 351 (1998) 28-31
39. The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design. The DIRECT Programme Study Group, J. Renin Angiotensin Aldosterone Syst. 3 (2002) 255-261.
40. The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics. The DIRECT Programme Study Group. J. Renin Angiotensin Aldosterone Syst. 6 (2005) 25-32.
41. Study rationale and design of ADVANCE: action in diabetes and vascular disease-preterax and diamicron MR controlled evaluation, Diabetologia 44 (2001) 1118-1120.
42. Kinoshita N., Kakehashi A., Inoda S., Itou Y., Kuroki M., Yasu T., et al. Effective and selective prevention of retinal leukostasis in streptozotocin-induced diabetic rats using gliclazide. Diabetologia 45 (2002) 735-739
43. Alberti K.G., Johnson A.B., and Taylor R. Gliclazide: metabolic and vascular effects-a perspective. Metabolism 41 5 Suppl. 1 (1992) 40-45